NTM 1634

Drug Profile

NTM 1634

Alternative Names: BoNT C/D; NTM-1634

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
  • Developer Ology Bioservices
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Severe acute respiratory syndrome

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 20 Mar 2017 Phase-I clinical trials in Botulism (In volunteers) in USA (IV)
  • 20 Mar 2017 Phase-I clinical trials in Influenza-A virus H1N1 subtype (In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top